Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 01 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-sep-01-2023-4

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 01, 2023, titled "Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg".

View Attachment

6ix hasn’t read this filing yet.

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases